Dynavax Technologies Corp - To Discuss the Interim Analysis of Ongoing Clinical Trial Evaluating HEPLISAV-B - Conference Call Transcript
Good afternoon, and good morning. I'm Dr. Randy Hyer, Vice President of Clinical Development and Medical Affairs at Dynavax Technologies Corporation. And I want to welcome everybody to our webinar today on our HBV-24, where I'll be presenting the immunogenicity and safety of HEPLISAV-B in hemodialysis patients. I need to mention that this webinar is a presentation that was accepted into the scientific sessions at the National Foundation for Infectious Diseases Annual Conference on Vaccinology Research that would have been held on March 24, 2020, in Washington. And this was to be my presentation that was accepted for the oral abstract sessions. Of course, COVID-19 has changed things, and I'm doing it now as a webinar.
I want to thank everybody for joining today. And I'll be presenting my slides. And at the end of the presentation, there will be an opportunity for questions. I request that if you kindly ask questions using the Q&A function at the bottom of the screen, I'll be able to see your
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
